Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Murlentamab - GamaMabs Pharma

Next Previous
Drug Profile

Murlentamab - GamaMabs Pharma

Alternative Names: 3C23K; Anti-AMHR2 monoclonal antibody - GamaMabs; Anti-MISRII humanised monoclonal antibody 3C23K; Anti-mullerian human receptor-II monoclonal antibody - GamaMabs; GM-102; Humanised monoclonal antibody 3C23K

Latest Information Update: 28 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LFB Biotechnologies
  • Developer GamaMabs Pharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Anti-Mullerian hormone receptor antagonists; Antibody-dependent cell cytotoxicity; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • No development reported Gynaecological cancer

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Gynaecological-cancer(Late-stage disease, Second-line therapy or greater) in Belgium (Parenteral)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Gynaecological-cancer(Late-stage disease, Second-line therapy or greater) in France (Parenteral)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Gynaecological-cancer(Late-stage disease, Second-line therapy or greater) in United Kingdom (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top